

Biochemistry

Spiro-epoxyglycosides as Activity-Based Probes for Glycoside Hydrolase Family 99 Endomannosidase/Endomannanase

Sybrin P. Schröder,^[a] Wouter W. Kallemeijn,^[b] Marjoke F. Debets,^[a] Thomas Hansen,^[a] Lukasz F. Sobala,^[c] Zalihe Hakki,^[d] Spencer J. Williams,^[d] Thomas J. M. Beenakker,^[a] Johannes M. F. G. Aerts,^[b] Gijsbert A. van der Marel,^[a] Jeroen D. C. Codée,^[a] Gideon J. Davies,^{*,[c]} and Herman S. Overkleeft^{*,[a]}

Abstract: N-Glycans direct protein function, stability, folding and targeting, and influence immunogenicity. While most glycosidases that process N-glycans cleave a single sugar residue at a time, enzymes from glycoside hydrolase family 99 are *endo*-acting enzymes that cleave within complex N-glycans. Eukaryotic Golgi *endo*-1,2- α -mannosidase cleaves glucose-substituted mannose within immature glucosylated high-mannose N-glycans in the secretory pathway. Certain bacteria within the human gut microbiota produce *endo*-1,2- α -mannanase, which cleaves related structures within fungal mannan, as part of nutrient acquisition. An unconventional

mechanism of catalysis was proposed for enzymes of this family, hinted at by crystal structures of imino/azasugars complexed within the active site. Based on this mechanism, we developed the synthesis of two glycosides bearing a spiro-epoxide at C-2 as electrophilic trap, to covalently bind a mechanistically important, conserved GH99 catalytic residue. The spiro-epoxyglycosides are equipped with a fluorescent tag, and following incubation with recombinant enzyme, allow concentration, time and pH dependent visualization of the bound enzyme using gel electrophoresis.

Introduction

N-Linked glycans are complex oligosaccharides linked to asparagine (Asn) residues in eukaryotic proteins.^[1] They play important roles in protein function, stability, folding and targeting and are essential for a range of cellular functions.^[2] Erroneous N-glycan composition is associated with various diseases including viral infections, Alzheimer's disease and metastatic

cancer.^[3–5] Assembly of the N-glycan commences in the endoplasmic reticulum (ER) where the 14-mer polysaccharide Glc₃Man₉GlcNAc₂-diphosphodolichol is coupled to the Asn residue of the target protein by the enzyme oligosaccharyl transferase. The glycan undergoes stepwise “trimming” of the non-reducing end glucoside residues by α -glucosidase I and II, after which α -mannosidase I truncates the resulting oligomannoside.^[6] The resulting Man₅GlcNAc₂ structure is redecorated to yield complex N-glycans. Because α -glucosidases I and II play important roles in the early stages of glycan maturation, these enzymes were investigated as therapeutic targets to control diseases involving incorrect N-glycosylation.^[7–10] However, inhibition of these enzymes did not block N-glycosylation: mouse lymphoma cells inhibited with the α -glucosidase inhibitor castanospermine as well as mutant cell lines lacking α -glucosidase II retained up to 80% of normal N-glycan maturation.^[11–13] Spiro and co-workers identified *endo*-1,2- α -mannosidase,^[14,15] (later classified as a member of glycoside hydrolase family 99 (GH99); see <http://cazypedia.org>),^[16] residing in the Golgi apparatus, which circumvents inhibition of ER α -glucosidase I and II. The enzyme cleaves glucose-substituted mannose from the A-branch of ER escaped immature N-glycoproteins bearing Glc_{1–3}Man₉GlcNAc₂, releasing Glc_{1–3}Man. The resulting Man₈GlcNAc₂ glycoprotein subsequently re-enters the normal processing route in the Golgi apparatus.

Bacterial GH99 orthologs including *Bacteroides thetaiotaomicron* (Bt) and *Bacteroides xylanisolvens* (Bx) enzymes possess *endo*-1,2- α -mannosidase activity, but are more appropriately described as *endo*-1,2- α -mannanases, as they act on yeast

[a] Dr. S. P. Schröder, Dr. M. F. Debets, T. Hansen, Dr. T. J. M. Beenakker, Prof. Dr. G. A. van der Marel, Dr. J. D. C. Codée, Prof. Dr. H. S. Overkleeft
Department of Bioorganic Chemistry, Leiden Institute of Chemistry
Einsteinweg 55, 2333 CC Leiden (The Netherlands)
E-mail: h.s.overkleeft@chem.leidenuniv.nl

[b] Dr. W. W. Kallemeijn, Prof. Dr. J. M. F. G. Aerts
Department of Medical Biochemistry, Leiden Institute of Chemistry
Einsteinweg 55, 2333 CC Leiden (The Netherlands)

[c] L. F. Sobala, Prof. Dr. G. J. Davies
Department of Chemistry, York Structural Biology Laboratory
University of York, Heslington, York, YO10 5DD (UK)
E-mail: gideon.davies@york.ac.uk

[d] Dr. Z. Hakki, Prof. Dr. S. J. Williams
School of Chemistry and Bio21 Molecular Science and
Biotechnology Institute, University of Melbourne
Parkville, Victoria (Australia)

Supporting information and the ORCID identification numbers for the authors of this article can be found under:
<https://doi.org/10.1002/chem.201801902>.

© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of Creative Commons Attribution NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

mannan^[17] and exhibit a tenfold preference for mannan-based substrates versus the equivalent glucose-substituted mannans.^[18] Several imino/azasugar inhibitors for GH99 endomannosidase have been developed, including α -glucopyranosyl-1,3-isofagomine (GlcIFG, **1**, Figure 1) and α -mannopyranosyl-1,3-isofagomine (ManIFG, **2**). Due to a preference for a mannopyranosyl residue in subsite -2 GH99 *endo*-1,2- α -mannanases show a greater affinity for **2** than for **1**.^[18] Recently, mannoerythromycin (ManNOE, **3**), which features a 2-hydroxyl allowing interaction with the proposed general base/acid residue, has been reported as the most potent *endo*-1,2- α -mannanase inhibitor for bacterial GH99 enzymes with K_D values in the low nanomolar range.^[19] Additionally, fluorescent^[20] and fluorogenic^[18,21] substrates have been developed for monitoring *endo*-1,2- α -mannosidase/mannanase activity.

Family GH99 *endo*-1,2- α -mannosidases/mannanases cleave their substrate glycosides with retention of anomeric stereochemistry; however, instead of the classical Koshland double-displacement mechanism for retaining enzymes,^[22] an unusual neighboring group participation hydrolytic mechanism was proposed in which a glutamate residue (Glu₃₃₃ in *BxGH99*) acts as a general base assisting OH-2 to displace the aglycon via a 1,2-anhydro sugar that is subsequently hydrolyzed by water (Figure 1 B).^[23] In order to study enzyme function in biological settings, screen for inhibitors, as well as to further illuminate

the catalytic reaction mechanism, the development of a mechanism-based irreversible inhibitor would be of interest. Here, the synthesis is described of two putative covalent inhibitors **4** and **5**, designed to, respectively inhibit eukaryotic GH99 *endo*-1,2- α -mannosidases and bacterial *endo*-1,2- α -mannanases and which vary in the nature of the pyranoside at the non-reducing end (Figure 1 A, right). Both compounds contain a spiro-epoxide at position C-2 to serve as an electrophile to trap the general base residue. Inspection of the crystal structures of *BxGH99* suggests that the general base will be situated close to the methylene group of the spiro-epoxide, where it may open the ring via nucleophilic attack resulting in a covalent intermediate (Figure 1 C).^[23] The compounds are also equipped with a reporter tag, allowing active enzyme labeling by activity-based protein profiling (ABPP)^[24] protocols, the efficiency of which is reported as well.

Results

Acceptor **7** was synthesized by 4,6-silylidene protection of compound **6**,^[25] followed by formation of the 2,3-ortho-benzoate and final treatment with acid (Scheme 1).^[26] Glucopyranoside donor **9** was synthesized from thiophenyl β -glucopyranoside **8**.^[27] While 4,6-silylidene protection proceeded smoothly, elevated temperatures were required to install the TBS-





Figure 1. (A) Known GH99 *endo*-1,2- α -mannosidase inhibitors (**1–3**) and fluorescent spiro-epoxyglycosides **4** and **5** subject of this study. K_D values are for *B. thetaiotaomicron* *endo*-1,2- α -mannosidase (*BtGH99*). (B) The proposed catalytic mechanism for GH99 enzyme (amino acid numbering for *B. xylanisolvens* *endo*-1,2- α -mannosidase (*BxGH99*)). (C) Anticipated covalent inhibition mechanism of GH99 enzymes.



Scheme 1. Synthesis of fluorescent spiro-epoxyglycosides **4** and **5**. Reagents and conditions: a) $t\text{Bu}_2\text{Si}(\text{OTf})_2$, 2,6-lutidine, DMF, -50°C ; b) $\text{PhC}(\text{OMe})_3$, CSA, 2 h, then AcOH , H_2O , 16 h, 57% over 2 steps; c) TBSOTf, DMAP, pyridine, 60°C , 16 h, yield **9**: 85% over 2 steps; yield **11**: 81% over 2 steps; d) donor **9** or **11**, NIS, TMSOTf, DCM, 4 Å MS, -40°C , 1 h, yield **12g**: 92%; yield **12m**: 88%; e) NaOMe, MeOH, DCM, yield **13g**: 95%; yield **13m**: 86%; f) DMP, DCM, yield **14g**: 98%; yield **14m**: 96%; g) TBAF, THF, 5 days, yield **17**: 97%; yield **18**: 74%; h) Cy5-alkyne,^[47] $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, sodium ascorbate, DMF, rt, 16 h, yield **4**: 32%; yield **5**: 34%.

groups onto both secondary hydroxyl groups, presumably due to steric hindrance. Using a similar approach, thiophenyl α -mannopyranoside **10**^[28] was converted to protected thiomannoside donor **11**.

Glycosylation of acceptor **7** by **9** or **11** was achieved in an *N*-iodosuccinimide (NIS)/trimethylsilyl triflate (TMSOTf) mediated coupling at low temperature, affording **12g** or **12m**, respectively. Both glycosylations proceeded in excellent yield and stereoselectivity. Pedersen, Bols and co-workers^[29] recently reported that silylidene-protected mannosyl donors can be used for stereoselective β -mannosylation. The contrasting selectivity obtained here is likely the result of the steric buttressing effect of the large silyl ether protecting groups at the C-2- and C-3-hydroxyls of **7**, consistent with the steric effects that large protecting groups and functionalities have in glycosylations of otherwise β -selective benzylidene-protected mannosyl donors.^[30] Thus, the β -face of mannosyl donor **11** is shielded from attack by the incoming nucleophile. The glycosylation stereoselectivity of glucosyl donor **9** can be rationalized by its high reactivity. The "arming" silyl protecting groups allow this donor to readily form an oxocarbenium ion, which will likely take up a $^4\text{H}_3$ -like conformation, which is preferentially attacked from the α -face to provide the 1,2-*cis*-linked product.^[31,32] Next, the benzoyl groups were deprotected under Zemplén conditions affording compounds **13g** and **13m**. The alcohols were then oxidized with Dess–Martin periodinane (DMP) to ketones **14g** and **14m**, which appeared to be in equilibrium with the corresponding hydrates.

Transformation of ketones **14** into their corresponding spiro-epoxides was explored next (Table 1). Reaction of **14g** with diazomethane as methylenating agent^[33] resulted in the formation of the equatorial (**15g**) and axial (**16g**) methylenes in a 1:1 ratio and in good yields (entry 1). Their absolute configuration was determined by 1D-NOE difference experiments (see Supplementary Information). Reaction of **14m** with diazomethane also resulted in a mixture of **15m** and **16m**, in a 3:1

Table 1. Transformation of ketones **14g** and **14m** into their corresponding spiro-epoxides.

Entry	s.m.	Conditions	15:16	Yield [%] ^[a]
1	14g	CH_2N_2 , EtOH, 0°C	1:1	78
2	14m	CH_2N_2 , EtOH, 0°C	3:1	97
3	14g	SOMe_3 , <i>n</i> BuLi, THF, 60°C	1:5	83
4	14m	SOMe_3 , <i>n</i> BuLi, THF, 60°C	1:2	85
5	14g	SMe_3 , NaH, DMSO, THF, -10°C	0:1	50
6	14m	SMe_3 , NaH, DMSO, THF, -10°C	0:1	53

[a] Combined yield after column chromatography. s.m. = starting material.

ratio, in favor of the equatorial methylene group in almost quantitative yield (entry 2). We anticipated that a Corey–Chaykovsky epoxidation^[34] using stabilized dimethylsulfoxonium methylide would favor the formation of the equatorial methylenes **15g** and **15m**. Indeed, also in these cases both isomers were obtained, however the formation of axial methylenes was still favored in both cases (entries 3 and 4). Finally, using the more reactive dimethylsulfoxonium methylide, only the kinetically favored axial methylenes **16g** and **16m** were formed, albeit in moderate yields (entries 5 and 6). With spiro-epoxides **16g** and **16m** in hand, global deprotection was accomplished by reaction with tetrabutylammonium fluoride (TBAF). Finally, a fluorescent Cy5 tag was installed at the azide handle using copper(I) catalyzed click chemistry, which after HPLC purification afforded spiro-epoxyglycosides **4** and **5**.

The ability of **4** and **5** to label recombinant *Bt*- and *BxGH99* *endo*-1,2- α -mannanase was evaluated (Figure 2A). The compounds label both enzymes in a concentration-dependent manner, at concentrations as low as 100 nM. Previous studies indicated a preference for a mannosyl residue at the -2 subsite of both enzymes.^[18] However, no difference in potency of labeling was observed. Studies on the effect of the pH dependence on labeling revealed that both spiro-epoxyglycosides label the enzymes maximally at pH 6–8, corresponding to




Figure 2. Fluorescent labeling of GH99 endomannanases. (A) Detection limit of *Bt* and *Bx* GH99 endomannanases (left and right, respectively), labeled with various concentrations of fluorescent spiro-epoxyglycosides **4** or **5**. (B) Effect of pH on labeling of *Bt* and *Bx* GH99 enzymes with **4** or **5**. (C) Labeling of wild-type and mutant *Bx*GH99 with **4** or **5** (left or right, respectively) for 5, 15 or 30 minutes. (D) Effect of denaturation with 1% (w/v) SDS and boiling on labeling of *Bt* and *Bx* GH99 enzymes (left and right, respectively) with **4** or **5**. The marker is annotated with an asterisk (*).

the pH optimum of GH99 enzymatic activity (Figure 2B).^[23] Notably, more than one band is evident, suggesting enzyme degradation under reducing SDS-PAGE conditions or alternatively that multiple labelling events may be occurring. Next, labeling of wild-type (WT) *Bx*GH99 was compared to analogous active-site mutants (Figure 2C). While WT enzyme is labeled by spiro-epoxyglycosides **4** and **5** within 5 minutes, the general base mutant E333Q and the catalytic acid mutant E336Q were not labeled in the same time period with these compounds, suggesting that labeling is indeed activity-based, and is consistent with reaction occurring in a mechanism-based manner. However, incubation for longer times resulted in labeling of the mutant enzymes, indicating that either the spiro-epoxide is susceptible to ring opening by the mutant catalytic residues, or that other residues may also be involved in covalent labelling. Denaturation of *Bt*GH99 and *Bx*GH99 completely abrogated labeling by spiro-epoxyglycosides **4** and **5**, indicating that labeling requires the natively folded enzyme (Figure 2D).

To further evaluate whether covalent inhibition of *Bt*GH99 and *Bx*GH99 is activity-based, the processing of human α -galactosidase A (GLA) by these enzymes was investigated (Figure 3A). GLA contains three N-glycosylation sites, of which two are decorated with oligo-mannose structures, and one contains complex oligosaccharides low in mannose content.^[35,36] We have previously demonstrated that fluorescent α -galacto-cyclophellitol aziridines such as TB340 covalently label GLA in activity-based manner.^[37] Here, GLA was pre-labeled with TB340 to enable fluorescent detection on gel. Without additives, GLA gives a distinct major band at ≈ 50 kDa (Figure 3B, lane 1). Incubation of GLA with *Bt*GH99 results in demannosylation of the two high-mannose N-glycans of GLA, resulting in a shift of the GLA band into lower bands at ≈ 42 kDa (lane 2). This shift in molecular weight is

similar to the shift observed when GLA is incubated with Endo-H (lane 4), which causes demannosylation of high-mannose N-glycans by cleaving within the chitobiosyl core leaving a residual GlcNAc on Asn. Treatment of GLA with PNGase-F




Figure 3. (A) Schematic representation of processing of human α -galactosidase GLA by GH99 endomannosidase. GLA is pre-labeled by fluorescent TB340, and contains high-mannose N-glycans which can be truncated by endomannosidase, resulting in a decrease in GLA molecular weight. Activity-based labeling of endomannosidase by spiro-epoxyglycosides **4** or **5** (prior to incubation with GLA) blocks its activity, and is therefore unable to process GLA. (B) *Bt*GH99 wild-type demannosylates GLA, causing a shift in molecular weight for the protein bands. Pre-labeling *Bt*GH99 wild-type with **4** or **5** abrogates GLA demannosylation. Endo-H cleaves high-mannose structures, PNGase-F cleaves full N-linked glycan (leaving Asp-GlcNAc). (C) *Bx*GH99 wild-type demannosylates GLA, while *Bx*GH99 pre-labeled with **4** or **5** is unable to do so. *Bx*GH99 active-site mutants E333Q and E3336Q are unable to process GLA. (D) Fluorescent labeling of *Bt*GH99 (top) and *Bx*GH99 (bottom) by **4** or **5** competed by different concentrations of **17**, **18**, ManIFG (**2**) and yeast mannan. The marker is annotated with an asterisk (*).

(lane 5), which cleaves most N-glycans leaving Asn, results in a band of a lower molecular weight, most likely as a result of complete deglycosylation of all three N-glycans. When *BtGH99* was pre-incubated with **4** or **5**, demannosylation of TB340-labeled GLA was mostly inhibited (lane 3), indicating that binding of **4** and **5** occurs in the *BtGH99* active site. An identical experiment was conducted with *BxGH99* wildtype and the E333Q and E336Q mutant enzymes (Figure 3C). Similar to *BtGH99*, wildtype *BxGH99* is able to process the N-glycans decorating the surface of the enzyme, giving rise to a shift in molecular weight (lane 2), similar to processing by Endo-H (lane 8). Pre-incubation of WT *BxGH99* by **4** or **5**, prior to consecutive incubation with TB340-labeled GLA resulted in an observed absence of glycan processing (lane 3), indicating that binding of **4** and **5** abrogates enzymatic activity. Interestingly, while mutants E333Q and E336Q are labeled by spiro-epoxyglycosides **4** and **5** after prolonged reaction times, they are evidently unable to process TB340-labeled GLA (lanes 4–7).

Finally, the inhibitory potencies of **2**, **17**, **18** and yeast mannan from *S. cerevisiae* (an α -1,6-linked mannose backbone branched with α -1,2 and α -1,3 mannoses)^[38] towards *BtGH99* were investigated using spiro-epoxyglycoside **5** as fluorescent read-out (Figure 3D). The enzyme was first pre-incubated with the competitor for 30 min at 37 °C, followed by labeling with 1 μ M **5**. Compounds **17** and **18** both show a concentration-dependent competition of fluorescent labeling in the range of 10–1,000 μ M, although full competition with labeling could not be achieved under these conditions. Similarly, the azasugar ManIFG (**2**) gave concentration-dependent competition but again full competition was not achieved. However, pre-incubation by yeast mannan achieved full competition with labeling, suggesting that processing of spiro-epoxyglycoside **5** by *BtGH99* endomannanase is specific and activity based. A similar competition experiment was performed for *BxGH99*, and it was shown that while pre-incubation with **17** did not fully abrogate labeling, pre-incubation with 1000 μ M of **18** provided full competition, possibly hinting at a slight preference for a mannosyl residue in subsite –2. Additionally, yeast mannan showed concentration dependent (albeit incomplete) competition, and azasugar **2** fully competed with labeling at 1,000 μ M, suggesting that processing of spiro-epoxyglycoside **5** by *BxGH99* is specific and activity-based.

Discussion

Epoxide-based probes have been investigated as mechanism-based inhibitors of a range of glycosidases. Early work led to the development of epoxyalkyl glycosides,^[39] which were initially proposed as reagents that could specifically label the nucleophile of retaining glycosidases, however X-ray crystallography later revealed labelling of both acid/base and nucleophile residues.^[40] In one classic study, conduritol C epoxide, which was originally believed to label the nucleophile of *E. coli LacZ* β -galactosidase, was subsequently shown to covalently label the acid/base catalyst.^[41] Work from our laboratory has investigated related pyranose-mimicking cyclophellitol epoxides and aziridines and shown that these typically exhibit excellent se-

lectivity for labelling the nucleophile of assorted α - and β -glycosidases.^[42] We have shown that introduction of a reporter tag (e.g. biotin or a fluorescent dye) onto these small molecule inhibitors affords chemical probes that enable quantification of activity,^[43,44] and have distinct advantages over techniques such as transcription analysis and antibody-based detection. We report here the first activity-based probes for detection of GH99 enzymes, which were designed based on the proposed mechanism of this enzyme. In this proposed mechanism a 1,2-anhydro-epoxide intermediate is formed by general base assisted deprotonation of O2 by a carboxylate residue.^[23] Our design strategy includes a reactive C2 spiro-epoxide that can potentially covalently label the general base (acting as a nucleophile), and includes a fluorescent label for visualization. Gel-based analysis of labelled bacterial GH99 *endo*-1,2- α -mannanases demonstrated concentration dependent labelling which occurs in a pH dependent manner consistent with the pH optimum of enzyme activity. Labelling could be competed by various substrates and inhibitors, providing evidence that it is active-site directed. While mutation of the key general base and general acid residues inactivated the enzyme towards processing of natural substrate N-glycans in GLA, the mutants could be labelled with the spiro-epoxyglycosides, albeit with reduced potency. Collectively, our data suggests that these spiro-epoxides do result in labelling at the active site, presumably through the catalytic general base. However, the high reactivity of the primary epoxide means that labelling is most likely not exclusive at a single residue. While *endo*-1,2- α -mannanase has a preference for mannosyl residues at the –2 binding subsite, there was minimal differences in the efficiency of labelling for spiro-epoxides bearing either a mannosyl or glucosyl residue. We believe these compounds represent an important first step in devising probes that take advantage of the unique mechanism proposed for this family. Future studies will seek to better understand the mode of labelling by identifying the covalently labelled residue(s) by X-ray crystallography or MS based techniques. By analogy to previously described irreversible cyclophellitol activity-based probes,^[43] we propose these fluorescent spiro-epoxyglycosides could ultimately lead to chemical tools for functional investigation of GH99 *endo*-1,2- α -mannosidase/mannanases, both as isolated species and in tissue extracts.

Experimental Section

Chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, Fluka, Merck and Fisher Scientific and used as received unless stated otherwise. Tetrahydrofuran (THF), *N,N*-dimethylformamide (DMF) and toluene were stored over molecular sieves before use. All reactions were performed under an argon atmosphere unless stated otherwise. TLC analysis was conducted using Merck aluminum sheets (Silica gel 60 F₂₅₄) with detection by UV absorption (254 nm), by spraying with a solution of (NH₄)₆Mo₇O₂₄·4H₂O (25 g L⁻¹) and (NH₄)₄Ce(SO₄)₄·2H₂O (10 g L⁻¹) in 10% sulfuric acid, followed by charring at \approx 150 °C. Column chromatography was performed using Screening Device b.v. silica gel (particle size of 40–63 μ m, pore diameter of 60 Å) with the indicated eluents. For reversed-phase HPLC purifications an Agilent Tech-

nologies 1200 series instrument equipped with a semi-preparative column (Gemini C18, 250×10 mm, 5 μm particle size, Phenomenex) was used. ¹H NMR and ¹³C NMR spectra were recorded on a Brüker AV-400 (400 and 101 MHz, respectively) or a Brüker DMX-600 (600 and 151 MHz, respectively) spectrometer in the given solvent. Chemical shifts are given in ppm (δ) relative to the residual solvent peak or tetramethylsilane (0 ppm) as internal standard. High-resolution mass spectrometry (HRMS) analysis was performed with a LTQ Orbitrap mass spectrometer (Thermo Finnigan), equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min⁻¹, capillary temperature 250 °C) with resolution *R* = 60 000 at *m/z* 400 (mass range *m/z* 150–2000) and dioctyl phthalate (*m/z* 391.28428) as lock mass. The high-resolution mass spectrometer was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). ManIFG was prepared as previously reported.^[18] Recombinant expression of *B. thetaiotaomicron* (*Bt*) and *B. xylanisolvens* (*Bx*) GH99 was achieved as previously described.^[23] Recombinant α-galactosidase (GLA) was purchased from Genzyme (Cambridge, MA, USA). The α-galactosidase ABP TB340 was synthesized as described earlier.^[37] Yeast mannan from *S. cerevisiae* was purchased from Sigma.

Synthesis and characterization

(4*aR*,6*S*,7*S*,8*R*,8*aS*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-hydroxyhexahydroprano[3,2-*d*][1,3,2]dioxasilin-7-yl benzoate (7): Compound **6**^[45] (1.00 g, 3.80 mmol) was co-evaporated with dry toluene and dissolved in dry DMF (38 mL). The resulting solution was cooled to -50 °C and *Sit*Bu₂(OTf)₂ (1.11 mL, 3.42 mmol, 0.9 EQ) and 2,6-lutidine (0.44 mL, 3.80 mmol) were added. The reaction was stirred at -50 °C for 30 minutes and subsequently quenched with brine (400 mL). The aqueous layer was extracted with Et₂O (4×100 mL). The combined organic layers were washed with 1 M aqueous HCl (2×100 mL), H₂O (100 mL), and brine and dried over Na₂SO₄. The solvents were removed under reduced pressure and the crude product was purified by gradient column chromatography (EtOAc/pentane, 1:4 to 1:2). The 4,6-silydene product was obtained as white solid (970 mg, 70%). ¹H NMR (400 MHz, CDCl₃): δ = 4.81 (d, *J* = 1.4 Hz, 1H), 4.11 (dd, *J* = 10.0, 5.0 Hz, 1H), 4.07–4.00 (m, 2H), 3.96 (t, *J* = 10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.69 (td, *J* = 10.0, 5.0 Hz, 1H), 3.50 (ddd, *J* = 10.0, 6.3, 5.2 Hz, 1H), 3.40 (td, *J* = 6.6, 2.0 Hz, 2H), 1.94–1.82 (m, 2H), 1.06 (s, 9H), 1.00 ppm (s, 9H). ¹³C NMR (101 MHz, CDCl₃): δ = 166.0, 133.4, 129.9, 129.7, 128.5, 98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8, 20.0 ppm. IR (neat): $\tilde{\nu}$ = 3524, 2934, 2886, 2097, 1732, 1717, 1558, 1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm⁻¹. [α]_D²⁰ (c 0.1, DCM): -16. HRMS (ESI) *m/z*: [*M*+Na]⁺ calcd for C₂₄H₃₇N₃O₇SiNa 530.22930, found 530.22907. The 4,6-silydene compound (889 mg, 2.20 mmol) was dissolved in trimethyl orthobenzoate (5.7 mL) and CSA (102 mg, 0.44 mmol) was added. The reaction was stirred for 2 hours at room temperature and cooled to 0 °C. Aqueous AcOH (50%, 20 mL) was added and the mixture was stirred overnight while the cooling bath was allowed to reach room temperature. The solution was poured into saturated aqueous NaHCO₃ (50 mL) and the water layer was extracted with CH₂Cl₂ (3×50 mL). The combined organic layers were washed with NaHCO₃ (50 mL) and dried over MgSO₄. The solvents were removed under reduced pressure and the crude product was purified by gradient column chromatography (EtOAc/pentane, 1:99 to 1:10). The title product was obtained as colorless oil (922 mg, 82%). ¹H NMR (400 MHz, CDCl₃): δ = 8.15–7.98 (m, 2H), 7.63–7.54 (m, 1H), 7.51–7.41 (m, 2H), 5.42 (dd, *J* = 3.4, 1.6 Hz, 1H), 4.88 (d, *J* = 1.4 Hz, 1H), 4.23–4.06 (m, 3H), 3.99 (t, *J* = 10.2 Hz, 1H), 3.86–3.76 (m, 2H), 3.59–3.49 (m, 1H), 3.43 (t, *J* = 6.6 Hz, 2H), 1.99–1.81 (m, 2H), 1.09 (s, 9H), 1.02 ppm (s, 9H).

¹³C NMR (101 MHz, CDCl₃): δ = 166.0, 133.4, 129.9, 129.7, 128.5, 98.1, 75.2, 72.0, 70.2, 67.4, 66.6, 64.6, 48.2, 28.8, 27.4, 27.0, 22.8, 20.0 ppm. IR (neat): $\tilde{\nu}$ = 3524, 2934, 2886, 2097, 1732, 1717, 1558, 1472, 1267, 1095, 1072, 1026, 885, 826, 710, 654 cm⁻¹. [α]_D²⁰ (c 0.1, DCM): -16. HRMS (ESI) *m/z*: [*M*+Na]⁺ calcd for C₂₄H₃₇N₃O₇SiNa 530.22930, found 530.22907.

(4*aR*,6*S*,7*R*,8*S*,8*aR*)-2,2-Di-*tert*-butyl-7,8-bis((*tert*-butyldimethylsilyloxy)-6-(phenylthio)hexahydroprano[3,2-*d*][1,3,2]dioxasilin (9): Compound **8**^[27] (2.6 g, 9.5 mmol) was dissolved in dry DMF (100 mL) under Ar-atmosphere. The mixture was cooled to -50 °C and 2,6-lutidine (3.3 mL, 28.5 mmol) and *Sit*Bu₂(OTf)₂ (3.4 mL, 10.5 mmol) was added. The reaction was stirred for 2 hours at -50 °C and subsequently quenched with H₂O (100 mL). The water layer was extracted with EtOAc (3×100 mL). The organic layers were combined and washed with H₂O (2×200 mL) and brine (200 mL) and dried over MgSO₄. The solvents were removed under reduced pressure and the crude product was purified by gradient column chromatography (EtOAc/pentane, 1:4 to 1:2). The 4,6-silydene product was obtained as a white solid (3.58 g, 91%). ¹H NMR (400 MHz, CDCl₃): δ = 7.57–7.46 (m, 2H), 7.38–7.28 (m, 3H), 4.60 (d, *J* = 9.7 Hz, 1H), 4.21 (dd, *J* = 10.2, 5.1 Hz, 1H), 3.90 (t, *J* = 10.2 Hz, 1H), 3.68 (t, *J* = 9.0 Hz, 1H), 3.60 (t, *J* = 8.7 Hz, 1H), 3.51–3.37 (m, 2H), 2.92 (s, 1H), 2.77 (s, 1H), 1.04 (s, 9H), 0.98 ppm (s, 9H). ¹³C NMR (101 MHz, CDCl₃): δ = 132.9, 131.7, 129.1, 128.3, 88.6, 77.8, 76.4, 74.5, 71.8, 66.1, 27.4, 27.0, 22.7, 19.9. IR (neat): $\tilde{\nu}$ = 3241, 2932, 2858, 1695, 1471, 1058 cm⁻¹. [α]_D²⁰ (c 0.06, DCM): -57.0. HRMS (ESI) *m/z*: [*M*+Na]⁺ calcd for C₂₀H₃₂O₅SSiNa 435.16319, found 435.16315. The 4,6-silydene product (1.0 g, 2.42 mmol) was co-evaporated with toluene (3×), dissolved in dry pyridine (5 mL) and cooled to 0 °C. DMAP (30 mg, 0.24 mmol) and TBSOTf (3.33 mL, 14.5 mmol) were added and the mixture was heated to 60 °C and stirred overnight. The mixture was carefully diluted with water (25 mL) and extracted with DCM (3×50 mL). The combined organic layers were washed with aq. 1 M HCl (3×25 mL) and brine, dried over Na₂SO₄, filtrated and concentrated. The crude product was purified by gradient column chromatography (pentane/EtOAc, 400:1 to 200:1), affording the title product as a white solid (1.44 g, 93%). Analytical data were in accordance with those reported in literature.^[46]

(4*aR*,6*R*,7*S*,8*S*,8*aR*)-2,2-Di-*tert*-butyl-7,8-bis((*tert*-butyldimethylsilyloxy)-6-(phenylthio)hexahydroprano[3,2-*d*][1,3,2]dioxasilin (11): The 4,6-silydene compound was prepared from **10**^[28] (4.9 g, 18 mmol) as described for the preparation of **9** to afford the product (6.6 g, 89%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.52–7.20 (m, 5H), 5.53 (s, 1H), 4.30 (d, *J* = 3.1 Hz, 1H), 4.24 (td, *J* = 10.0, 5.0 Hz, 1H), 4.15–4.08 (t, *J* = 9.4 Hz, 1H), 4.05 (dd, *J* = 10.0, 5.0 Hz, 1H), 3.96 (t, *J* = 10.1 Hz, 1H), 3.87 (dd, *J* = 9.1, 3.3 Hz, 1H), 2.67 (brs, 2xOH), 1.05 (s, 9H), 1.03 ppm (s, 9H). ¹³C NMR (101 MHz, CDCl₃): δ = 133.9, 131.5, 129.3, 127.7, 87.8, 75.0, 72.4, 72.1, 67.9, 66.2, 27.6, 27.2, 22.8, 20.2 ppm. IR (neat): $\tilde{\nu}$ = 3384, 2932, 2858, 1474, 1064 cm⁻¹. [α]_D²⁰ (c 0.4, DCM): +227. HRMS (ESI) *m/z*: [*M*+Na]⁺ calcd for C₂₀H₃₂O₅SSiNa 435.16319, found 435.16301. The title product was prepared from the 4,6-silydene compound (6.6 g, 16 mmol) as described for the preparation of **9** to afford the product (9.3 g, 91%) as a pale yellow oil which crystallized at -20 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.48–7.25 (m, 5H), 5.29 (d, *J* = 1.5 Hz, 1H), 4.28 (t, *J* = 9.0 Hz, 1H), 4.19 (m, 1H), 4.17–4.11 (m, 1H), 4.11–4.08 (m, 1H), 3.96 (t, *J* = 9.7 Hz, 1H), 3.87 (dd, *J* = 8.9, 2.5 Hz, 1H), 1.09 (s, 9H), 1.07 (s, 9H), 0.99 (s, 9H), 0.92 (s, 9H), 0.21 (s, 3H), 0.18 (s, 3H), 0.14 (s, 3H), 0.07 ppm (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ = 134.9, 131.3, 129.3, 127.4, 89.9, 75.0, 74.6, 73.0, 69.6, 67.1, 27.8, 27.3, 26.3, 25.8, 22.9, 20.2, 18.5, 18.2, -3.9, -4.1, -4.4, -4.4 ppm. IR (neat): $\tilde{\nu}$ = 2931, 2857, 1471, 1250, 1096 cm⁻¹. [α]_D²⁰ (c 1.0, DCM):

+91. HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{32}H_{61}O_5SSi_3$ 641.35420, found 641.36460.

(4*aR*,6*S*,7*S*,8*R*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*R*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethylsilyloxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-6-yl)oxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-7-yl benzoate (12 g): Compound **9** (2.00 g, 3.12 mmol) and compound **7** (1.58 g, 3.12 mmol) were combined and co-evaporated with toluene (3 ×). The mixture was dissolved in dry CH_2Cl_2 (20 mL) and stirred with activated 4A MS for 30 minutes at room temperature. The reaction was cooled to $-50^\circ C$ and NIS (842 mg, 3.74 mmol) and TMSOTf (68 μL , 0.37 mmol) were added. The reaction mixture was warmed to $-40^\circ C$, stirred for 1 hour and subsequently neutralized with NEt_3 (2 mL). The mixture was diluted with CH_2Cl_2 (200 mL) and washed with saturated aqueous Na_2SO_3 (2 × 100 mL), H_2O (100 mL) and subsequently dried over $MgSO_4$. The solvents were removed under reduced pressure and the crude product was purified by gradient column chromatography (EtOAc/pentane, 1:50 to 1:40). The title product was obtained as a white foam (2.98 g, 92%). 1H NMR (400 MHz, $CDCl_3$): δ = 8.08 (d, J = 7.3 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 2H), 5.49 (s, 1H), 5.16 (d, J = 2.9 Hz, 1H, H-1 "donor"), 4.86 (s, 1H, H-1 "acceptor"), 4.44 (t, J = 9.4 Hz, 1H), 4.22–4.15 (m, 2H, H-3), 4.04 (t, J = 10.2 Hz, 1H), 3.95–3.79 (m, 3H), 3.75–3.66 (m, 2H), 3.61 (t, J = 8.4 Hz, 1H), 3.54 (dt, J = 10.2, 5.7 Hz, 1H), 3.49–3.41 (m, 2H), 1.91 (dq, J = 13.5, 6.9 Hz, 1H), 1.13 (s, 9H), 1.04 (s, 9H), 1.03 (s, 9H), 0.97 (s, 9H), 0.91 (s, 9H), 0.79 (s, 9H), 0.17 (s, 3H), 0.05 (s, 3H), 0.03 ppm (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ = 165.4, 133.2, 129.9, 129.6, 128.5, 98.1, 97.9, 78.6, 75.2, 74.3, 73.4, 72.6, 71.1, 67.8, 67.8, 66.9, 66.6, 64.4, 48.1, 28.9, 27.5, 27.1, 27.0, 26.4, 26.2, 22.7, 22.7, 20.0, 20.0, 18.1, 18.0, –3.2, –3.5, –3.6, –4.4 ppm. ^{13}C -HMBC-GATED NMR (101 MHz, $CDCl_3$): δ = 98.1 ($J_{C1,H1}$ = 170.6 Hz, C1 "donor"), 97.9 ($J_{C1,H1}$ = 172.1 Hz, C1 "acceptor"). IR (neat): $\tilde{\nu}$ = 2966, 2859, 2093, 1732, 1472, 1260, 1096, 1069, 1045, 827 cm^{-1} . $[\alpha]_D^{20}$ (c 0.1, DCM): +20. HRMS (ESI) m/z : $[M+Na]^+$ calcd for $C_{50}H_{91}N_3O_{12}Si_4 + Na$ 1060.55720, found 1060.55694.

(4*aR*,6*S*,7*S*,8*R*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*S*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethylsilyloxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-6-yl)oxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-7-yl benzoate (12 m): This compound was prepared from **11** (378 mg, 0.59 mmol) and **7** (299 mg, 0.59 mmol) as described for the preparation of **12 g**, to afford the title product (538 mg, 88%) as a pale yellow oil. 1H NMR (400 MHz, $CDCl_3$): δ = 8.02 (m, 2H), 7.62–7.53 (m, 1H), 7.45 (t, J = 7.7 Hz, 2H), 5.34 (dd, J = 3.5, 1.6 Hz, 1H), 4.96 (d, J = 1.9 Hz, 1H), 4.82 (d, J = 1.4 Hz, 1H), 4.28 (t, J = 9.5 Hz, 1H), 4.15 (m, 3H), 4.08 (dd, J = 9.4, 3.6 Hz, 1H), 4.02–3.93 (t, J = 10.3 Hz, 1H), 3.90–3.77 (m, 4H), 3.77–3.67 (m, 2H), 3.57–3.37 (m, 3H), 2.02–1.77 (m, 2H), 1.09 (s, 9H), 1.04–1.00 (s, 9H), 1.00 (s, 9H), 0.95–0.89 (m, 9H), 0.87–0.82 (m, 9H), 0.82–0.76 (m, 9H), 0.07 (s, 3H), 0.00 (s, 3H), –0.13 (s, 3H), –0.17 ppm (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ = 165.5, 133.4, 130.0, 129.7, 128.6, 103.4, 98.2, 75.2, 75.1, 74.0, 73.6, 72.4, 71.8, 69.5, 67.7, 67.5, 67.1, 64.8, 48.4, 29.0, 27.9, 27.7, 27.2, 27.2, 26.2, 25.8, 22.9, 22.9, 20.1, 19.9, 18.4, 18.2, –4.3, –4.4, –4.4, –4.7 ppm. ^{13}C -HMBC-GATED NMR (101 MHz, $CDCl_3$): δ = 103.4 ($J_{C1,H1}$ = 172.1 Hz, C1 "donor"), 98.2 ppm ($J_{C1,H1}$ = 172.5 Hz, C1 "acceptor"). IR (neat): $\tilde{\nu}$ = 2931, 2858, 20998, 1729, 1472, 1226, 1096, 1068 cm^{-1} . $[\alpha]_D^{20}$ (c 0.4, DCM): +1. HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{50}H_{92}N_3O_{12}Si_4$ 1038.57526, found 1038.57587.

(4*aR*,6*S*,7*S*,8*R*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*R*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethylsilyloxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-6-yl)oxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-7-ol (13 g): Compound **12 g** (610 mg, 0.59 mmol) was co-evaporated with toluene (3 ×) and dis-

solved in a mixture of DCM/MeOH (9 mL, 1:1). NaOMe (30 wt%, 560 μL) was added and the reaction mixture was stirred for 24 h. The reaction was neutralized with AcOH and the solvents were removed under reduced pressure. The crude product was purified by gradient column chromatography (EtOAc/pentane, 1:11 to 1:8). The title product was obtained as a white foam (519 mg, 95%). 1H NMR (400 MHz, $CDCl_3$): δ = 5.34 (d, J = 3.1 Hz, 1H), 4.81 (d, J = 0.7 Hz, 1H), 4.29 (t, J = 9.3 Hz, 1H), 4.10–4.02 (m, 2H), 3.98 (t, J = 10.3 Hz, 1H), 3.95 (s, 1H), 3.88 (dd, J = 9.2, 3.3 Hz, 1H), 3.86–3.76 (m, 3H), 3.76–3.66 (m, 3H), 3.58 (dd, J = 8.2, 3.1 Hz, 1H), 3.54–3.47 (m, 1H), 3.38 (td, J = 6.5, 1.7 Hz, 2H), 3.00 (s, 1H, OH), 1.94–1.78 (m, 2H), 1.05 (s, 9H), 1.04 (s, 9H), 1.00 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.09 ppm (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ = 99.7, 97.4, 78.7, 75.1, 74.6, 74.5, 74.3, 71.1, 67.6, 67.4, 67.0, 66.4, 64.4, 48.4, 29.0, 27.6 (3 ×), 27.5 (3 ×), 27.2 (3 ×), 27.1 (3 ×), 26.4 (3 ×), 26.4 (3 ×), 22.9, 22.7, 20.1, 20.1, 18.3, 18.3, –3.1, –3.3, –3.4, –3.9 ppm. IR (neat): $\tilde{\nu}$ = 2931, 2856, 2099, 1472, 1252, 1132, 1095, 1069, 1043, 868, 827, 772, 654 cm^{-1} . $[\alpha]_D^{20}$ (c 0.1, DCM): +44. HRMS (ESI) m/z : $[M+Na]^+$ calcd for $C_{43}H_{87}N_3O_{11}Si_4 + Na$ 956.53099, found 956.53097.

(4*aR*,6*S*,7*S*,8*R*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*S*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethylsilyloxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-6-yl)oxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-7-ol (13 m): This compound was prepared from **12 m** (501 mg, 0.48 mmol) as described for the preparation of **13 g** to afford the title product (386 mg, 86%) as a colorless oil. 1H NMR (400 MHz, $CDCl_3$): δ = 5.00 (d, J = 1.9 Hz, 1H), 4.79 (d, J = 1.1 Hz, 1H), 4.17 (t, J = 9.2 Hz, 1H), 4.11 (m, 3H), 3.99–3.88 (m, 4H), 3.88–3.82 (m, 2H), 3.82–3.77 (m, 1H), 3.77–3.62 (m, 2H), 3.49 (m, 1H), 3.40 (td, J = 6.5, 3.1 Hz, 1H), 2.37–2.03 (brs, OH), 1.97–1.77 (m, 2H), 1.04 (m, 18H), 0.99 (s, 9H), 0.97 (s, 9H), 0.93 (s, 9H), 0.86 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.02 ppm (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ = 103.2, 99.6, 77.7, 74.5, 74.1, 73.3, 72.4, 71.5, 69.6, 67.4, 67.33, 66.8, 64.5, 48.4, 28.9, 27.8, 27.6, 27.2, 27.1, 26.3, 25.8, 22.9, 22.7, 20.1, 18.6, 18.2, –3.9, –4.1, –4.3, –4.6 ppm. IR (neat): $\tilde{\nu}$ = 2930, 2858, 2098, 1472, 1250, 1096, 1031 cm^{-1} . $[\alpha]_D^{20}$ (c 0.4, DCM): +32. HRMS (ESI) m/z : $[M+H]^+$ calcd for $C_{43}H_{88}N_3O_{11}Si_4$ 934.54904, found 934.54959.

(4*aR*,6*S*,8*S*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*R*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethylsilyloxy)hexahydropyrano[3,2-*d*][1,3,2]dioxasilin-6-yl)oxy)tetrahydropyrano[3,2-*d*][1,3,2]dioxasilin-7(6*H*)-one (14 g): Compound **13 g** (2.20 g, 2.36 mmol) was co-evaporated with dry toluene (3 ×) and dissolved in dry CH_2Cl_2 (65 mL). Dess–Martin periodinane (2.00 g, 4.71 mmol) was added and the mixture was stirred overnight. Celite was added and the solvents were removed under reduced pressure. The product was purified by gradient column chromatography (EtOAc/pentane, 1:70 to 1:4). The title product was obtained as a white foam (2.15 g, 98%). 1H NMR (400 MHz, $CDCl_3$): δ = 5.18 (d, J = 2.8 Hz, 1H), 4.73–4.72 (m, 2H), 4.24–4.02 (m, 5H), 4.02–3.90 (m, 1H), 3.90–3.73 (m, 3H), 3.67 (t, J = 8.6 Hz, 1H), 3.62–3.54 (m, 2H), 3.40 (t, J = 6.6 Hz, 2H), 1.94–1.81 (m, 2H), 1.06 (s, 9H), 1.04 (s, 9H), 1.02 (s, 9H), 0.98 (s, 9H), 0.93 (s, 9H), 0.92 (s, 9H), 0.17 (s, 3H), 0.12 (s, 3H), 0.11 (s, 3H), 0.08 ppm (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ = 196.2, 100.2, 98.2, 80.0, 78.9, 78.7, 74.9, 73.9, 67.49, 67.45, 67.0, 66.0, 65.3, 48.0, 27.5, 27.4 (3 ×), 27.1 (3 ×), 27.0 (3 ×), 26.5 (3 ×), 26.41 (3 ×), 22.7, 22.6, 20.0, 20.0, 18.3, 18.1, –3.0, –3.5, –3.7, –3.9 ppm. IR (neat): $\tilde{\nu}$ = 2932, 2859, 2099, 1757, 1474, 1387, 1362, 1252, 1161, 1093, 1070, 1043, 866, 827, 775, 652 cm^{-1} . $[\alpha]_D^{20}$ (c 0.1, DCM): +50. HRMS (ESI) m/z : $[M+Na]^+$ calcd for $C_{43}H_{85}N_3O_{11}Si_4 + Na$ 954.51534, found 954.51535.

(4*aR*,6*S*,8*S*,8*aR*)-6-(3-Azidopropoxy)-2,2-di-*tert*-butyl-8-(((4*aR*,6*R*,7*S*,8*S*,8*aR*)-2,2-di-*tert*-butyl-7,8-bis(*tert*-butyldimethyl-

9H), 1.06 (s, 9H), 1.03 (s, 9H), 1.01 (s, 9H), 0.96 (s, 9H), 0.87 (s, 9H), 0.15 (s, 3H), 0.14 (s, 3H), 0.11 (s, 3H), 0.03 ppm (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ = 102.1, 101.3, 79.0, 74.4, 73.5, 72.6, 68.7, 67.4, 67.2, 66.9, 64.5, 58.3, 48.2, 47.6, 28.9, 27.7, 27.7, 27.2, 27.1, 26.3, 25.7, 22.8, 22.8, 20.2, 20.1, 18.7, 18.2, -4.0, -4.1, -4.3, -4.6 ppm. IR (neat): ν̄ = 2931, 2098, 1741, 1251, 1159, 1097 cm⁻¹. [α]_D²⁰ (c 0.05, DCM): +44. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₄₄H₈₈N₃O₁₁Si₄ 946.54904, found 946.54933.

(2R,3R,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-Azidopropoxy)-7-hydroxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (17): Compound **16g** (145 mg, 0.153 mmol) was co-evaporated with toluene (3×) and dissolved in dry THF (14.5 mL). TBAF (1 M in THF, 2.3 mL, 2.3 mmol) was added and the mixture was stirred 5 days at room temperature. The solution was eluted with THF over a small Dowex-50WX4-200-Na⁺ packed column, concentrated and purified by gradient column chromatography (EtOAc/MeOH, 19:1 to 9:1). The product was dissolved in water and lyophilized to afford the title compound as a white solid (64.8 mg, 97%). ¹H NMR (400 MHz, D₂O): δ = 5.23 (d, *J* = 3.8 Hz, 1H), 4.50 (s, 1H), 4.25 (d, *J* = 9.0 Hz, 1H), 3.95–3.68 (m, 8H), 3.63–3.53 (m, 2H), 3.53–3.43 (m, 3H), 3.41–3.34 (t, *J* = 8 Hz, 1H), 3.17 (d, *J* = 4.5 Hz, 1H), 2.87 (d, *J* = 4.6 Hz, 1H), 1.97–1.85 ppm (m, 2H). ¹³C NMR (101 MHz, D₂O): δ = 100.0, 99.2, 73.0, 72.9, 72.5, 71.7, 71.5, 70.91, 69.1, 64.8, 60.3, 60.2, 58.7, 48.4, 48.1, 27.8 ppm. IR (neat): ν̄ = 3369, 2927, 2108, 1521, 1026 cm⁻¹. [α]_D²⁰ (c 0.1, DCM): +174. HRMS (ESI) *m/z*: [M+NH₄]⁺ calcd for C₁₆H₃₁N₄O₁₁ 455.19838, found 455.19849.

(2R,3S,4S,5S,6R)-2-(((3R,4S,6R,7R,8S)-4-(3-azidopropoxy)-7-hydroxy-6-(hydroxymethyl)-1,5-dioxaspiro[2.5]octan-8-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (18): This compound was prepared from **16m** (59 mg, 0.623 mmol) as described for the preparation of **17** to afford the title product (20 mg, 74%) as a white solid. ¹H NMR (400 MHz, D₂O): δ = 5.05 (d, *J* = 1.6 Hz, 1H), 4.45 (s, 1H), 4.18 (d, *J* = 9.3 Hz, 1H), 3.95 (dd, *J* = 3.2, 1.8 Hz, 1H), 3.77 (m, 6H), 3.64 (m, 3H), 3.57–3.48 (m, 1H), 3.41 (t, *J* = 6.5 Hz, 2H), 3.10 (d, *J* = 4.5 Hz, 1H), 2.81 (d, *J* = 4.5 Hz, 1H), 1.95–1.78 ppm (m, 2H). ¹³C NMR (101 MHz, D₂O): δ = 101.0, 100.0, 73.3, 72.8, 72.5, 70.9, 70.4, 69.9, 66.3, 64.7, 60.8, 60.2, 58.7, 48.3, 48.0, 27.8 ppm. HRMS (ESI) *m/z*: [M+Na]⁺ calcd for C₁₆H₂₇N₃O₁₁ 460.1538, found 460.1544.

1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium (4): Compound **17** (4.83 mg, 11.0 μmol) was dissolved in DMF (0.5 mL) and placed under Argon. Then the Cy5-alkyne⁴⁷ (6.1 mg, 11.0 μmol), aq. CuSO₄ (0.1 M, 44 μL, 4.4 μmol) and aq. sodium ascorbate (0.1 M, 44 μL, 4.4 μmol) were added and the mixture was stirred overnight at room temperature. The product was purified by HPLC (50 mM NH₄CO₃) to afford the title compound as a blue solid (3.54 mg, 32%). ¹H NMR (400 MHz, MeOD): δ = 8.24 (t, *J* = 13.0 Hz, 2H), 7.89 (s, 1H), 7.49 (d, *J* = 7.4 Hz, 2H), 7.44–7.38 (m, 2H), 7.32–7.23 (m, 4H), 6.62 (t, *J* = 12.4 Hz, 1H), 6.28 (d, *J* = 13.7 Hz, 2H), 5.14 (d, *J* = 3.8 Hz, 1H), 4.85 (s, 1H), 4.53 (t, *J* = 6.8 Hz, 2H), 4.42 (s, 2H), 4.32 (s, 1H), 4.16 (d, *J* = 9.1 Hz, 1H), 4.10 (t, *J* = 7.4 Hz, 2H), 3.84–3.64 (m, 9H), 3.63 (s, 3H), 3.56 (t, *J* = 9.3 Hz, 1H), 3.40 (dd, *J* = 9.7, 3.8 Hz, 1H), 3.37–3.32 (1, 9H), 3.07 (d, *J* = 5.3 Hz, 1H), 2.70 (d, *J* = 5.4 Hz, 1H), 2.25 (t, *J* = 7.3 Hz, 2H), 2.23–2.15 (m, 2H), 1.88–1.76 (m, 2H), 1.75–1.67 (m, 17H), 1.51–1.44 ppm (m, 2H). ¹³C NMR (101 MHz, MeOD): δ = 180.3, 175.7, 175.4, 174.7, 155.5, 155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3, 126.2, 124.7, 123.4, 123.3, 112.0, 111.9, 104.4, 104.3, 102.4,

101.8, 76.8, 75.1, 74.4, 74.0, 73.9, 73.0, 71.2, 65.3, 62.4, 62.4, 59.8, 50.6, 50.5, 48.4, 44.8, 36.5, 35.6, 31.5, 31.0, 28.1, 27.9, 27.8, 27.3, 26.4 ppm. HRMS (ESI) *m/z*: [M]⁺ calcd for C₅₁H₆₉N₆O₁₂ 957.4968, found 957.5005.

1-(6-(((1-(3-(((3R,4S,6R,7R,8S)-7-Hydroxy-6-(hydroxymethyl)-8-(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,5-dioxaspiro[2.5]octan-4-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-6-oxohexyl)-3,3-dimethyl-2-((1E,3E)-5-((Z)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium (5): This compound was prepared from **18** (3.72 mg, 8.5 μmol) as described for the preparation of **4** to afford the product (2.9 mg, 34%) as a blue solid. ¹H NMR (600 MHz, MeOD): δ = 8.24 (t, *J* = 13.0 Hz, 2H), 7.90 (s, 1H), 7.49 (d, *J* = 7.4 Hz, 2H), 7.44–7.39 (m, 2H), 7.28 (dt, *J* = 16.4, 7.6 Hz, 4H), 6.62 (t, *J* = 12.4 Hz, 1H), 6.28 (d, *J* = 13.7 Hz, 2H), 5.19 (d, *J* = 1.3 Hz, 1H), 4.85 (s, 1H), 4.54 (t, *J* = 6.8 Hz, 2H), 4.42 (s, 2H), 4.29 (s, 1H), 4.23 (d, *J* = 9.2 Hz, 1H), 4.10 (t, *J* = 7.4 Hz, 3H), 3.90 (dd, *J* = 3.2, 1.7 Hz, 1H), 3.85–3.68 (m, 9H), 3.66 (d, *J* = 9.5 Hz, 1H), 3.63 (s, 3H), 3.60 (dd, *J* = 9.5, 3.3 Hz, 1H), 3.57–3.52 (m, 1H), 3.36–3.32 (m, 1H), 3.01 (d, *J* = 5.3 Hz, 1H), 2.68 (d, *J* = 5.4 Hz, 1H), 2.26 (t, *J* = 7.3 Hz, 2H), 2.20 (dq, *J* = 13.1, 6.7 Hz, 2H), 1.83 (m, 2H), 1.73 (s, 17H), 1.47 ppm (m, 2H). ¹³C NMR (150 MHz, MeOD): δ = 180.3, 175.7, 175.4, 174.7, 155.5, 155.5, 146.1, 144.3, 143.6, 142.6, 142.5, 129.8, 129.7, 126.6, 126.3, 126.2, 124.8, 123.4, 123.3, 112.1, 111.8, 104.4, 104.3, 102.6, 102.4, 74.7, 74.3, 74.1, 73.3, 72.7, 72.1, 68.2, 65.2, 62.7, 62.3, 59.9, 50.6, 50.5, 48.3, 44.8, 36.5, 35.7, 31.5, 31.1, 31.0, 28.1, 28.0, 27.8, 27.3, 26.4 ppm. HRMS (ESI) *m/z*: [M]⁺ calcd for C₅₁H₆₉N₆O₁₂ 957.4968, found 957.4995.

Labeling of BtGH99 and BxGH99 enzymes

To determine the detection limit, 400 ng recombinant *B. thetaiotaotao-micron* (Bt) and *B. xylanisolvans* (Bx) GH99 enzymes were labeled in 150 mM Mcllvaine buffer, pH 7.0 (citric acid-Na₂HPO₄) with 0.0001–10 μM spiro-epoxyglycoside **4** or **5** for 1 h at 37 °C. The samples were then denatured with 5× Laemmli buffer (50% (v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) 100% (w/v) glycerol, 10% (w/v) DTT, 10% (w/v) SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at 100 °C, and separated by electrophoresis on 10% (w/v) SDS-PAGE gel running continuously at 90 V.^[43] Wet slab-gels were scanned on fluorescence using a Typhoon FLA 9500 (GE Healthcare) at λ_{EX} 532 nm and λ_{EM} 575 nm for ABP TB340; and at λ_{EX} 635 nm and λ_{EM} 665 nm for **4** and **5**. The pH optimum was analyzed using 4 ng enzyme incubated with 1 μM **4** or **5** dissolved in Mcllvaine buffer, pH 3–8, for 30 min at 37 °C. Time-dependent labeling of BxGH99 wild-type, E333Q and E336Q enzymes was assessed by incubating 400 ng for 5, 15 or 30 min with 1 μM **4** or **5** dissolved in Mcllvaine buffer, pH 7.0. The effect of denaturation was assessed on 4 ng wild-type BtGH99 and BxGH99 by boiling for 4 min at 100 °C prior to incubating with 1 μM **4** and **5** for 30 min at 37 °C. Competitive ABPP assays utilized 4 ng BtGH99 and BxGH99 enzyme that was pre-incubated with 10–1000 μM **17**, **18** or ManIFG, or 0.3–30 μg μL⁻¹ yeast mannan (*S. cerevisiae*), at pH 7.0 for 30 min at 37 °C, followed by labeling with 1 μM **4** and **5** for 30 min at 37 °C.

Functional GLA assay

Recombinant α-galactosidase GLA was diluted 1:2 in 50 mM Mcllvaine buffer, pH 4.6, and pre-labeled with 2 μM TB340 for 1 h at 37 °C. Subsequently, the mixture was diluted to 1:500 in 150 mM Mcllvaine buffer, pH 7.0. In parallel, 400 ng BxGH99 wild-type, E333Q and E336Q were incubated in the presence or absence of 10 μM **4** or **5**, dissolved in 150 mM Mcllvaine buffer, pH 7.0, for 1 h at 37 °C. Subsequently, the BxGH99 mixture (10 μL) was incubated

with 10 μ L TB340-labeled GLA for 8 h at 37 °C. Hereafter, samples were denatured, separated on SDS-PAGE gel and visualized by fluorescence scanning, as described above (vide supra). As control, 10 μ L TB340-labeled GLA was treated by either Endo-H or PNGase-F, following the manufacturer's instructions (New England Biolabs).

Acknowledgements

We thank the Netherlands Organization for Scientific Research (NWO-CW ChemThem grant to JMFGA and HSO), and the European Research Council (ERC-2011-AdG-290836 "Chembiosphing" to HSO, and ERC-2012-AdG-32294 "Glycopoise" to GJD). GJD thanks the Royal Society for the Ken Murray Research Professorship.

Conflict of interest

The authors declare no conflict of interest.

Keywords: activity-based probes · endomannosidase · GH99 · glycosidase · inhibitors

- [1] A. Helenius, M. Aebi, *Science* **2001**, *291*, 2364.
- [2] M. Molinari, *Nat. Chem. Biol.* **2007**, *3*, 313.
- [3] T. Feizi, M. Larkin, *Glycobiology* **1990**, *1*, 17.
- [4] Y.-Y. Zhao, M. Takahashi, J.-G. Gu, E. Miyoshi, A. Matsumoto, S. Kitazume, N. Taniguchi, *Cancer Sci.* **2008**, *99*, 1304.
- [5] K. Akasaka-Manya, H. Manya, Y. Sakurai, B. S. Wojczyk, Y. Kozutsumi, Y. Saito, N. Taniguchi, S. Murayama, S. L. Spitalnik, T. Endo, *Glycobiology* **2010**, *20*, 99.
- [6] A. Herscovics, *Biochim. Biophys. Acta Gen. Subj.* **1999**, *1473*, 96.
- [7] Y. T. Pan, H. Hori, R. Saul, B. A. Sanford, R. J. Molyneux, A. D. Elbein, *Biochemistry* **1983**, *22*, 3975.
- [8] V. W. Sasak, J. M. Ordovas, A. D. Elbein, R. W. Berninger, *Biochem. J.* **1985**, *232*, 759.
- [9] L. Foddy, R. C. Hughes, *Eur. J. Biochem.* **1988**, *175*, 291.
- [10] R. G. Spiro, *J. Biol. Chem.* **2000**, *275*, 35657.
- [11] S. E. H. Moore, R. G. Spiro, *J. Biol. Chem.* **1990**, *265*, 13104.
- [12] K. Fujimoto, R. Kornfeld, *J. Biol. Chem.* **1991**, *266*, 3571.
- [13] C. Völker, C. M. De Praeter, B. Hardt, W. Breuer, B. Kalz-Füller, R. N. Van Coster, E. Bause, *Glycobiology* **2002**, *12*, 473.
- [14] W. A. Lubas, R. G. Spiro, *J. Biol. Chem.* **1987**, *262*, 3775.
- [15] W. A. Lubas, R. G. Spiro, *J. Biol. Chem.* **1988**, *263*, 3990.
- [16] a) V. Lombard, H. G. Ramulu, E. Drula, P. M. Coutinho, B. Henrissat, *Nucleic Acids Res.* **2014**, *42*, D490–D495; b) The Cazylopedia Consortium, *Glycobiology* **2017**, *28*, 3.
- [17] F. Cuskin, E. C. Lowe, M. J. Temple, Y. Zhu, E. A. Cameron, N. A. Pudlo, N. T. Porter, K. Urs, A. J. Thompson, A. Cartmell, A. Rogowski, B. S. Hamilton, R. Chen, T. J. Tolbert, K. Piens, D. Bracke, W. Verweken, Z. Hakki, G. Speciale, J. L. Munöz-Munöz, A. Day, M. J. Peña, R. McLean, M. D. Suits, A. B. Boraston, T. Atherly, C. J. Ziemer, S. J. Williams, G. J. Davies, D. W. Abbott, E. C. Martens, H. J. Gilbert, *Nature* **2015**, *517*, 165.
- [18] Z. Hakki, A. J. Thompson, S. Bellmaine, G. Speciale, G. J. Davies, S. J. Williams, *Chem. Eur. J.* **2015**, *21*, 1966.
- [19] M. Petricevic, L. F. Sobala, P. Z. Fernandes, L. Raich, A. J. Thompson, G. Bernardo-Seisdedos, O. Millet, S. Zhu, M. Sollogoub, J. Jiménez-Barbero, C. Rovira, G. J. Davies, S. J. Williams, *J. Am. Chem. Soc.* **2017**, *139*, 1089.
- [20] S. Iwamoto, Y. Kasahara, K. I. Kamei, A. Seko, Y. Takeda, Y. Ito, I. Matsuo, *Biosci. Biotechnol. Biochem.* **2014**, *78*, 927.
- [21] C. Vogel, G. Pohlentz, *J. Carbohydr. Chem.* **2000**, *19*, 1247.
- [22] D. E. Koshland, *Biol. Rev.* **1953**, *28*, 416.
- [23] A. J. Thompson, R. J. Williams, Z. Hakki, D. S. Alonzi, T. Wennekes, T. M. Gloster, K. Songsrirote, J. E. Thomas-Oates, T. M. Wrodnigg, J. Spreitz, A. E. Stutz, T. D. Butters, S. J. Williams, G. J. Davies, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 781.
- [24] B. F. Cravatt, A. T. Wright, J. W. Kozarich, *Annu. Rev. Biochem.* **2008**, *77*, 383.
- [25] Y. Zhang, C. Chen, L. Jin, H. Tan, F. Wang, H. Cao, *Carbohydr. Res.* **2015**, *401*, 109.
- [26] G. Despras, R. Robert, B. Sendid, E. MacHez, D. Poulain, J. M. Mallet, *Bioorg. Med. Chem.* **2012**, *20*, 1817.
- [27] M. S. Motawia, C. E. Olsen, K. Enevoldsen, J. Marcussen, B. L. Møller, *Carbohydr. Res.* **1995**, *277*, 109.
- [28] M. Martín-Lomas, N. Khair, S. García, J. L. Koessler, P. M. Nieto, T. W. Rademacher, *Chem. Eur. J.* **2000**, *6*, 3608.
- [29] M. Heuckendorff, J. Bendix, C. M. Pedersen, M. Bols, *Org. Lett.* **2014**, *16*, 1116.
- [30] D. Crich, V. Dudkin, *Tetrahedron Lett.* **2000**, *41*, 5643.
- [31] S. van der Vorm, T. Hansen, H. S. Overkleeft, G. A. van der Marel, J. D. C. Codée, *Chem. Sci.* **2017**, *8*, 1867.
- [32] S. Van der Vorm, H. S. Overkleeft, G. A. Van der Marel, J. D. C. Codée, *J. Org. Chem.* **2017**, *82*, 4793.
- [33] K. Sato, J. Yoshimura, *Carbohydr. Res.* **1979**, *73*, 75.
- [34] E. J. Corey, M. Chaykovsky, *J. Am. Chem. Soc.* **1965**, *87*, 1353.
- [35] S. C. Garman, D. N. Garboczi, *J. Mol. Biol.* **2004**, *337*, 319.
- [36] Y. Sohn, J. M. Lee, H. R. Park, S. C. Jung, T. H. Park, D. B. Oh, *BMB Rep.* **2013**, *46*, 157.
- [37] J. Jiang, T. J. M. Beenakker, W. W. Kallemeijn, G. A. van der Marel, H. van den Elst, J. D. C. Codée, J. M. F. G. Aerts, H. S. Overkleeft, *Chem. Eur. J.* **2015**, *21*, 10861.
- [38] T. Nakajima, C. E. Ballou, *J. Biol. Chem.* **1974**, *249*, 7685.
- [39] G. Legler, E. Bause, *Carbohydr. Res.* **1973**, *28*, 45.
- [40] R. Havukainen, A. Törrönen, T. Laitinen, J. Rouvinen, *Biochemistry* **1996**, *35*, 9617.
- [41] J. C. Gebler, R. Aebersold, S. G. Withers, *J. Biol. Chem.* **1992**, *267*, 11126.
- [42] L. I. Willems, J. Jiang, K. Y. Li, M. D. Witte, W. W. Kallemeijn, T. J. N. Beenakker, S. P. Schröder, J. M. F. G. Aerts, G. A. van der Marel, J. D. C. Codée, H. S. Overkleeft, *Chem. Eur. J.* **2014**, *20*, 10864.
- [43] M. D. Witte, W. W. Kallemeijn, J. Aten, K.-Y. Li, A. Strijland, W. E. Donker-Koopman, A. M. C. H. van den Nieuwendijk, B. Bleijlevens, G. Kramer, B. I. Florea, B. Hooibrink, C. E. M. Hollak, R. Ottenhoff, R. G. Boot, G. A. van der Marel, H. S. Overkleeft, J. M. F. G. Aerts, *Nat. Chem. Biol.* **2010**, *6*, 907.
- [44] W. W. Kallemeijn, K. Y. Li, M. D. Witte, A. R. A. Marques, J. Aten, S. Scheij, J. Jiang, L. I. Willems, T. M. Voorn-Brouwer, C. P. A. A. van Roomen, R. Ottenhoff, R. G. Boot, H. van den Elst, M. T. C. Walvoort, B. I. Florea, J. D. C. Codée, G. A. van der Marel, J. M. F. G. Aerts, H. S. Overkleeft, *Angew. Chem. Int. Ed.* **2012**, *51*, 12529; *Angew. Chem.* **2012**, *124*, 12697.
- [45] V. Ladmiral, G. Mantovani, G. J. Clarkson, S. Cauet, J. L. Irwin, D. M. Hadleton, *J. Am. Chem. Soc.* **2006**, *128*, 4823.
- [46] C. M. Pedersen, L. U. Nordstrøm, M. Bols, *J. Am. Chem. Soc.* **2007**, *129*, 9222.
- [47] O. Kaczmarek, H. A. Scheidt, A. Bunge, D. Föse, S. Karsten, A. Arbutzova, D. Huster, J. Liebscher, *Eur. J. Org. Chem.* **2010**, 1579.

Manuscript received: April 17, 2018

Revised manuscript received: May 23, 2018

Accepted manuscript online: May 24, 2018

Version of record online: June 21, 2018